Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis

NCT02708914 is registered in ClinicalTrials.gov with UBI Pharma Inc. as lead sponsor.

NCT NCT02708914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02708914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis
Lead sponsor
UBI Pharma Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2016
Completion date
October 31, 2021
Enrollment
269 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

renal anemia